Navigation Links
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
Date:9/10/2007

Results Show Improvements in RA Signs and Symptoms Compared to Placebo

SEATTLE, Sept. 10 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced preliminary analysis of results from a Phase IIb randomized, double-blind, placebo-controlled, multicenter clinical trial of its TRU-015 product candidate for rheumatoid arthritis (RA). The results indicated that Trubion's TRU-015 product candidate, at well-tolerated dosages, provided statistically significant improvements in RA signs and symptoms compared to placebo at 24 weeks. Trubion is co-developing TRU-015 with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), for the treatment of rheumatoid arthritis.

TRU-015 Phase IIb Clinical Trial Protocol and Results

The Phase IIb randomized, double-blind, placebo-controlled, multicenter clinical trial included 276 patients with rheumatoid arthritis who were also receiving methotrexate as background therapy. Patients in the Phase IIb study were randomized evenly into five groups that received either placebo, 200 mg, 400 mg, 800 mg or 1600 mg of TRU-015.

The study was designed to evaluate the safety and efficacy of a single intravenous infusion of TRU-015 compared to placebo for a 24-week period, with a primary endpoint of improvement on the Disease Activity Score (DAS)-28 scale at 12 weeks, and secondary endpoints including response rates at 24 weeks using American College of Rheumatology (ACR) criteria.

Preliminary analysis i
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... and sellers of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... 3,500 attendees from top pharmaceutical, fine chemical and specialty chemical ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... DIEGO, June 8, 2011 Otonomy, Inc., ... of the ear, today announced positive results for OTO-201, ... in multiple preclinical studies evaluating the treatment of middle ... placement surgery.  Approximately one million tube placement procedures are ...
... NORTH KINGSTOWN, R.I., June 8, 2011 Leading national ... Tufts Health Care Institute,s (THCI) Program on Opioid Risk ... support of THCI,s Program on Opioid Risk Management began ... promoting the safe and effective use of controlled opioid ...
Cached Medicine Technology:Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure 2Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure 3Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure 4Dominion Diagnostics Supports Opioid Risk Management Program for Fourth Consecutive Year 2
(Date:4/23/2014)... researcher is looking to give exercise enthusiasts the extra ... research shows that a cyber buddy can help. , ... Health Journal , is the first to indicate that ... during exercise, a software-generated partner also can be effective. ... real can still motivate people to give greater effort ...
(Date:4/23/2014)... N.Y. A novel compound that targets an important ... of cocaine addiction behaviors, including relapse behavior, a University ... provides strong evidence that this may be a novel ... effective medications exist., The UB research was published as ... week. , In the study, the compound, RO5263397, severely ...
(Date:4/23/2014)... 2014) The American Gastroenterological Association (AGA) Research ... Research Scholars. The AGA Research Scholar Awards program, ... independent and productive research careers in digestive diseases. ... an additional year allowing for three consecutive years ... junior faculty who are paving the way for ...
(Date:4/23/2014)... by a researcher from the Cancer Science Institute of ... has identified the cancer specific stem cell which causes ... developing new drugs for the treatment of this disease ... led by Dr Chan Shing Leng, Research Assistant Professor ... a cancer-specific variant of a cell surface protein, CD44v8-10, ...
(Date:4/23/2014)... shown that proliferation of endogenous neural precursor cells ... and axons. From the perspective of neural plasticity, ... University in China observed the effects of functional ... proliferation and expression of basic fibroblast growth factor ... on the infarct side. The researchers found that ...
Breaking Medicine News(10 mins):Health News:Cyber buddy is better than 'no buddy' 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3
... Longtime environmental health researchers at Tufts University School ... chemicals (EDCs), ubiquitous chemicals that have hormone-like effects ... online May 25 in Nature Reviews Endocrinology ... complex strategies for studying how these chemicals affect ...
... Cleveland Clinic finds that patients suffering from cirrhosis preceded ... developing hepatocellular carcinoma than those who develop cirrhosis resulting ... study appear in the June issue of Hepatology ... the American Association for the Study of Liver Diseases ...
... ... Healthcare providers can now easily access critical patient information in MxChart EMR software wherever ... ... and medical transcription services provider, MxSecure, Inc., today announced that MxChart, their EMR system, ...
... , ... stem cell in the developing human brain. The cell produces nerve cells that help form the ... of the region in the lineages that lead to man, the researchers say. ... (Vocus) May 25, 2010 -- UCSF scientists ...
... ... and earn money for college, by entering the B’nai B’rith International Diverse Minds Youth ... grade-schoolers about tolerance and diversity. The winners take home $5,000 college scholarships and will ... ...
... ... on Aerohive Controller-less WLAN Solution to Improve Patient Care and Cost Efficiencies ... Santa Clara, CA ... control wireless LAN (WLAN) architecture, announced today that LaVie Administrative Services, a provider of ...
Cached Medicine News:Health News:Endocrine-disrupting chemicals pose cancer risk 2Health News:New study confirms link between nonalcoholic steatohepatitis and liver cancer 2Health News:New study confirms link between nonalcoholic steatohepatitis and liver cancer 3Health News:MxSecure's Electronic Medical Record (EMR) Software, MxChart™, Now iPad Compatible 2Health News:Discovery of Stem Cell Illuminates Human Brain Evolution, Points To Therapies 2Health News:Discovery of Stem Cell Illuminates Human Brain Evolution, Points To Therapies 3Health News:Discovery of Stem Cell Illuminates Human Brain Evolution, Points To Therapies 4Health News:High School Students Well-Schooled In Diversity: Teen Winners of Book Writing Contest Earn College Scholarships and Have Entries Published 2Health News:LaVie Administrative Services Continues 1,200 Access Point Aerohive Roll Out to Address Electronic Medical Record Requirements 2Health News:LaVie Administrative Services Continues 1,200 Access Point Aerohive Roll Out to Address Electronic Medical Record Requirements 3Health News:LaVie Administrative Services Continues 1,200 Access Point Aerohive Roll Out to Address Electronic Medical Record Requirements 4
... Keep your samples secure in our largest ... storage - enough for 52,700 samples -- ... this ultra-low temperature model utilizes ultra-thin vacuum ... and minimize the footprint. Patented Tollesbury Technology ...
... III, laboratory-grade pure water at a constant ... potable tap water and combine complementary purification ... is easy to operate, reliable, and allows ... a low operating cost., Applications, Glassware ...
... U570 is an upright freezer, built ... models. Comparable in size to Innova ... cascade refrigeration and urethane insulation, for ... 400 2" boxes. Includes five compartments ...
... chest freezer utilizes ultra-thin vacuum insulation ... without increasing the footprint. Patented Tollesbury ... compressor life. Bright LED display shows ... for remote user-supplied monitoring system. Keyed ...
Medicine Products: